169 related articles for article (PubMed ID: 35445315)
1. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2022 Jun; 89(6):761-772. PubMed ID: 35445315
[TBL] [Abstract][Full Text] [Related]
2. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
4. Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS; Frenette CT; Keefe SM; Stein SM
Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
6. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Walko CM; Grande C
Semin Oncol; 2014 Feb; 41 Suppl 2():S17-28. PubMed ID: 24576655
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Tong X; Xu X; Shi H; Liu S; Yang Z
PLoS One; 2015; 10(2):e0117168. PubMed ID: 25689846
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
10. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
11. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Sasaki R; Fukushima M; Haraguchi M; Honda T; Miuma S; Miyaaki H; Nakao K
Medicine (Baltimore); 2022 May; 101(19):e29289. PubMed ID: 35583540
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib: key lessons from over 10 years of experience.
Escudier B; Worden F; Kudo M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):177-189. PubMed ID: 30575405
[No Abstract] [Full Text] [Related]
13. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Horiuchi-Yamamoto Y; Gemma A; Taniguchi H; Inoue Y; Sakai F; Johkoh T; Fujimoto K; Kudoh S
Int J Clin Oncol; 2013 Aug; 18(4):743-9. PubMed ID: 22752255
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Yu X; Guo G; Li X; Zhang C; Huang L; Fang D; Song Y; Zhang X; Zhou L
Medicine (Baltimore); 2015 Aug; 94(34):e1361. PubMed ID: 26313773
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
18. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Fairfax BP; Pratap S; Roberts IS; Collier J; Kaplan R; Meade AM; Ritchie AW; Eisen T; Macaulay VM; Protheroe A
BMC Cancer; 2012 Dec; 12():590. PubMed ID: 23231599
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
